Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal and other solid tumor malignancies.
In an interview with CancerNetwork®, Shubham Pant, MD, associate professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, highlighted key findings from a basket trial presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that examined the use of erdafitinib (Balversa) in gastrointestinal (GI) cancers.
One is a basket trial for patients with FGFR alterations, [including] driver mutations or fusions, with [treatment with] a drug called erdafitinib, which is an FGFR inhibitor. We presented the data at this ASCO in which we did a basket trial in non-bladder cancers, [including] a lot of GI cancers, glioblastoma, and other cancers. What we saw was that there was an overall response rate in this unselected tumor agnostic population of about 30%. What was even more exciting was that our patients with cholangiocarcinoma had response rates of up to 50% and patients with pancreatic cancer—a very hard to treat malignancies [with] outcomes that are not that great—had response rates of 30%. We were very excited about presenting the data at ASCO.
Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. J Clin Oncol. 2022;40(suppl 16):3007. doi: 10.1200/JCO.2022.40.16_suppl.3007